The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

Whether you're managing Type 1 or Type 2 diabetes, Canadian Insulin offers a wide selection of brand-name insulin products like Lantus, Humalog, and Novolog, all sourced from licensed Canadian ...

Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that ...

Indian drugmakers Biocon, Eris Lifesciences, and Wockhardt are ramping up insulin production to capture a growing global opportunity, as market leader Novo Nordisk scales back its presence in ...

The once-weekly insulin analog lowered A1c as effectively as once-daily formulations in three new trials in type 2 diabetes.

Civica will make generic versions of the three most popular brands of insulin — Lantus, Humalog and Novolog, which account for more than 80% of the U.S. market.

While tweaking your diet and eliminating unhealthy foods is vital, you don’t have to compromise on flavor or quality. Here ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Anyone hoping to start 2025 in a healthier vein may have looked to low-sugar alternatives. That may not always be wise.

Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

The two best-selling insulin brands in the country include Mixtard and Ryzodeg, both by Danish drugmaker Novo Nordisk. Mixtard alone has a market of over Rs 800 crore in India.